Last reviewed · How we verify

Sildenafil Citrate in G allele carrier

Vanderbilt University Medical Center · Phase 1 active Small molecule Quality 0/100

Sildenafil Citrate in G allele carrier is a Small molecule drug developed by Vanderbilt University Medical Center. It is currently in Phase 1 development. Also known as: viagra, revatio,.

At a glance

Generic nameSildenafil Citrate in G allele carrier
Also known asviagra, revatio,
SponsorVanderbilt University Medical Center
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sildenafil Citrate in G allele carrier

What is Sildenafil Citrate in G allele carrier?

Sildenafil Citrate in G allele carrier is a Small molecule drug developed by Vanderbilt University Medical Center.

Who makes Sildenafil Citrate in G allele carrier?

Sildenafil Citrate in G allele carrier is developed by Vanderbilt University Medical Center (see full Vanderbilt University Medical Center pipeline at /company/vanderbilt-university-medical-center).

Is Sildenafil Citrate in G allele carrier also known as anything else?

Sildenafil Citrate in G allele carrier is also known as viagra, revatio,.

What development phase is Sildenafil Citrate in G allele carrier in?

Sildenafil Citrate in G allele carrier is in Phase 1.

Related